An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Through the generous support of Regeneron, four times a year River Journal publishes the on-site report of a high school ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real ...

After the company filed for bankruptcy in March, this week, the sale of 23andMe was completed after previously being approved by a judge.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

TTAM Research Institute acquires 23andMe in a $305 million bankruptcy sale, transitioning the DNA testing giant to a ...

Ryan Richardson joined BioNTech in 2018 and has served as Chief Strategy Officer since January 2020. During his time at the Company, he contributed significantly to BioNTech’s successful development, ...

The decision follows the initial approval granted in September 2023, which covered patients aged five years and above.